Science

NEUVOGEN has taken a fundamentally different approach to solving cancer. Unlike other early-stage immunoncology companies, we try to solve for multiple issues arising from the complexity of cancer biology.

Our approach to solving cancer is based on the concept that in order to fully address the complexity of solid tumor cancer biology, many targets and multiple biologic pathways need to be addressed simultaneously.

Our Science

The science and technology behind NEUVOGEN holds the promise to overcome many of the biology-based limitations associated with earlier generations of whole cell tumor vaccines, including target optimization and magnitude of the generated immune response.

Tumors and immune cells constantly influence their surrounding microenvironment. Tumors can release extracellular signals, which promote tumor growth and induce immune escape. Suppressive immune cells in the microenvironment can also affect the growth and evolution of cancer cells.

NEUVOGEN’s system approach to solving cancer is multifaceted and focuses on maximizing the breadth and magnitude of the immune response while simultaneously trying to minimize the immunosuppressive effects of the tumor microenvironment.

Our Therapeutic Whole Cell Cancer Vaccine Platform

Our platform utilizes bioinformatic optimization of component cell lines along with proprietary combinations of genetic modifications to reduce immunosuppressive factors and enhance immunostimulatory factors within the vaccine microenvironment to provide the immune system with an unimpeded view of the cancer.

Immune targeting approaches typically focus on one or more selected targets, but some cancer cells within a tumor may not express these targets, leading to immune escape by the tumor.

In order to drive the deepest and most durable clinical response, NEUVOGEN’s proprietary platform is designed to theoretically target all the cancer cells within a tumor, and then amplify the immune response through multiple pathways. NEUVOGEN also addresses immunosuppression within the tumor microenvironment through various combination agents.